54 patients with acute viral hepatitis (8 of those having hepatic coma), 17 patients with unrecovered cirrhosis and 14 patients with hepatoma who were admitted in Bach Mai Hospital form March 1996 to May 1997 were involved in this study. Results showed that serum -GT level is often normally or lightly increased in fulminant hepatic failure and in unrecovered cirrhosis. This suggests that monitoring serum -GT may help to prognosticate for patient with acute viral hepatitis of cirrhosis. Serum -GT activity increases in hepatoma, so the estimation of this enzyme may help to diagnose the disease. Serum -GT activity increases in acute viral hepatitis but is less significance than serum transaminase (SGPT) in diagnosing the disease.
Liver Diseases ; Serum ; gamma-Glutamyltransferase

54 patients with acute viral hepatitis of which hepatic coma (8), uncompensate cirrhosis (17) and liver cancer (14) participated to a study have shown that the serum gamma glutamyl transpeptidase ((-GT) activity was slightly increased in patients with viral hepatitis coma and uncompensate cirrhosis. This was a bad sign the (-GT was highly increased in patients with liver cancer. The average serum (-GT activity was increased about 3 times in the acute viral hepatitis. But diagnostic value of (-GT was lower than this of SGPT
Liver Diseases ; Serum ; gamma-Glutamyltransferase ; Hepatic Encephalopathy

No abstract available.
Animals ; Autoradiography ; Carcinogenesis* ; Diethylnitrosamine ; gamma-Glutamyltransferase* ; Liver* ; Rats*

No abstract available.
Animals ; Autoradiography ; Carcinogenesis* ; Diethylnitrosamine ; gamma-Glutamyltransferase* ; Liver* ; Rats*

OBJECTIVES: Biochemical markers can provide an objective evidence of heavy alcohol drinking. The purpose of this study was to compare and evaluate the usefulness of biological markers detecting alcohol dependence, such as mean corpuscular volume(MCV), gamma-glutamyl transferase(GGT), and carbohydrate-deficient transferrin(CDT) in the patients of an alcohol counseling center. METHODS: This study was done with 64 patients with alcohol dependence and 36 healthy subjects. Relative values(%) of CDT were determined in their sera with turbidimetric immunoassay(Bio-Rad %CDT assay, Axis-Shield ASA, Oslo, Norway), and were compared with conventional markers of alcohol consumption, GGT and MCV. RESULTS: Among the patients with alcohol dependence, 78.1% showed abnormal %CDT levels compared with GGT(61.9%) and MCV(20.7%). The areas under the receiver operating characteristic(ROC) curves(95% confidence interval) for %CDT, GGT, and MCV were 0.934(0.866-0.973), 0.871(0.789-0.930), and 0.575 (0.472-0.673), respectively. CONCLUSION: %CDT seems to be the most reliable biological marker for the detection and monitoring of alcohol consumption in the patients with alcohol dependence of the alcohol counseling center.
Alcohol Drinking ; Alcoholism* ; Biomarkers* ; Counseling* ; Erythrocyte Indices ; gamma-Glutamyltransferase ; Humans

PURPOSE: To investigate the physical and biochemical parameters related with elevated serum alanine aminotransferase (ALT) levels in obese children. METHODS: One hundred forty-two obese or overweight children who visited the out-patient clinics of Chungnam National University Hospital between January 2006 and August 2008 were enrolled. Physical measures and biochemical tests were performed in all patients. Liver sonography was performed in 43 patients. They were divided into the following 2 groups based on ALT levels: group I, normal ALT levels (n=65); and group II, elevated ALT levels (n=77). We compared the physical measures, biochemical results, and ultrasonographic findings of the livers in both groups. Other causes of elevated serum ALT levels were ruled out. RESULTS: The male-to-female ratios were 1.6:1 in group I and 7.6:1 in group II. Among physical parameters, the waist circumference-to-height ratio and hip circumference-to-height ratio were significantly higher in group II (p=0.001 and 0.046, respectively). Among biochemical parameters, aspartate aminotransferase (AST), gamma-glutamyltransferase (gamma-GT), and total cholesterol levels were significantly higher in group II (p<0.001, 0.001, and 0.001, respectively). The AST/ALT ratio was <1 (mean, 0.55) and statistically lower in group II. There was a positive correlation between the serum ALT level and gamma-GT (p<0.001, r=0.750), and a positive correlation between the serum ALT level and the waist circumference-to-height ratio in group II (p<0.001, r=0.401). CONCLUSION: The results suggest that the waist circumference-to-height ratio and gamma-GT may be associated with elevated alanine aminotransferase activity in obese children.
Alanine ; Alanine Transaminase ; Aspartate Aminotransferases ; Child ; Cholesterol ; gamma-Glutamyltransferase ; Hip ; Humans ; Liver ; Outpatients ; Overweight

OBJECTIVETo explore the clinical effect of L-ornithine L-aspartate (LOLA) granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase (G-GT) using a 24-week treatment course.

METHODSTwo-hundred patients with chronic liver disease and above normal G-GT were given a 12-week course of LOLA granules (9 g/d) and then classified into the following three groups according to the change in serum Gamma-GT:group I:patients with Gamma-GT level returned to normal;group II:patients with serum Gamma-GT level that was reduced during the treatment; group III:patients with serum Gamma-GT level that did not decrease or that increased to a higher level than at start of treatment.After the 12-week treatment course, the patients in group I were divided into three subgroups for receipt of a control drug (compound glycyrrhizin, 50mg/d) or an additional 12-week course of Gamma-GT at a reduced dose (LOLA granules 3 g/d) or at the original dose; groups II and III were maintained on the initial dose for an additional 12 weeks.The groups were reassessed at the end of the second 12-week course (at the end of week 24 of the study's observation period).Count data were compared using the x2 test and measurement data were compared using the t-test.

RESULTSIn group I, the serum Gamma-GT level was 90.9% at the end of the first 12-week course and dropped to a mean level of 52.2% for both of the subgroups that received the reduced and original dose after the additional 12 weeks of LOLA granules treatment; the difference from week 12 to week 24 was significant (x2=8.213, P less than 0.05).The 24-week change in serum Gamma-GT levels for the group I reduced and original dose subgroups vs.the control subgroup were also significantly different from those seen in groups II and III (P less than 0.05).The percentage of patients in group I who achieved normal level serum Gamma-GT after 24 weeks of treatment (78.6%) was significantly higher than that for the control group (vs.55.0%, x2=11.452, P less than 0.05).When the patients in group 1 who had received the 12 additional weeks of LOLA granules treatment were measured again at two weeks after the treatments had been discontinued (end of week 26), the percentage of patients with normal serum Gamma-GT level was 92.7%, with only three cases showing obviously abnormal levels; in contrast, the group I patients in the control group of the second 12-week study period had on 66.7% of patients with normal-level serum Gamma-GT.The difference in change between the treated groups (both reduced and original dose) and the control group was significant (x2=14.964, P less than 0.05).

CONCLUSIONPatients whose serumGamma-GT levels returned to normal after receipt of LOLA granules for 12 weeks benefitted from an additional 12 weeks of consolidation treatment, and those given the treatment at the original dose benefitted most.Compared with the compound glycyrrhizin, LOLA granules provided a better maintenance of resolved Gamma-GT level.Therefore, the effect of LOLA appears to be reliable and stable as well as safe for clinical use.

Chronic Disease ; Dipeptides ; therapeutic use ; Humans ; Liver Diseases ; drug therapy ; Liver Function Tests ; gamma-Glutamyltransferase ; blood

BACKGROUND: Biochemical markers can provide objective evidence of heavy alcohol drinking. In this study, we investigated the diagnostic usefulness of carbohydrate-deficient transferrin (CDT), a relatively new marker of alcohol consumption. METHODS: We consecutively enrolled 81 participants aged between 28 and 69 years, consisting of 44 alcohol-dependent patients and 37 age-matched controls. Relative values (%) of CDT were determined in their sera with turbidimetric immunoassay (Bio-Rad %CDT assay, Axis-Shield ASA, Oslo, Norway), and were compared with two conventional markers of alcohol consumption, gammaglutamyl transferase (GGT) and mean corpuscular volume (MCV). RESULTS: The distribution patterns of %CDT among alcohol-dependent patients and controls were significantly different from each other (P=0.0000). Of the 44 alcohol-dependent patients, positive results of %CDT (> or =2.6%), GGT (>50 IU/L), and MCV (>98 fL) were observed in 43 (97.7%), 35 (79.5%), and 24 (54.5%) patients, respectively. The areas under the receiver operating characteristic (ROC) curves (95% confidence interval) for %CDT, GGT, and MCV were 0.995 (0.946-1.000), 0.894 (0.805-0.951), and 0.768 (0.661-0.855), respectively. Discrimination between alcohol-dependent patients and controls, as measured by the areas under the ROC curves, was significantly better for %CDT than for GGT and MCV (P=0.000 and P=0.006, respectively). CONCLUSIONS: CDT seems to be the most reliable of the three markers tested for chronic alcohol consumption, and it may provide a useful information to for the objective detection of alcohol-dependent patients.
Alcohol Drinking ; Alcoholism* ; Biomarkers ; Discrimination (Psychology) ; Erythrocyte Indices ; gamma-Glutamyltransferase ; Humans ; Immunoassay ; ROC Curve ; Transferases ; Transferrin*

OBJECTIVETo establish an automatic method for seminal plasma gamma-L-glutamyl transpeptidase (GGT) detection and evaluate its accuracy, repeatability and linear range.

METHODSWe detected the GGT activity in the seminal plasma by rate assay, and established the detection parameters on an automatic biochemical analyzer. Then, we evaluated the reagent blank absorbance, accuracy, repeatability and linear range of the automatic method, and compared the results obtained from the method and the seminal plasma GGT detection kit (Xindi Biological Pharmaceutical Engineering Co., Ltd, Nanjing, China) commonly used in clinical laboratories.

RESULTSThe average absorbance of reagent blank was 0.0476, and the average change rate of blank absorbance (deltaA/min) was 0.000168. The coefficients of variation (CV) for 3 seminal plasma samples with high, middle and low GGT activity detected for 10 times, respectively, were 0.26%, 4.83% and 1.60%. The accuracy of the automatic method was evaluated by a comparison test, and the relative deviation for each concentration point of 40 seminal plasma samples ranged from 13.38% to 11.05%, which met the requirement of < 15%. There was a good linear relationship (r > 0.99) when the seminal plasma GGT activity was between 299 and 1 833 U/L. A significant positive correlation was found between the seminal plasma GGT detection kit (a colorimetric method) as the control and the automatic method as the test reagent in the results of 115 seminal plasma samples (r = 0.981, P < 0.01), with a Kappa value of 0.776 (P < 0.05) and a coincidence rate of 90.43%.

CONCLUSIONThe established automatic method to detect seminal plasma GGT activity has a low reagent blank, good repeatability and accuracy, and fine concordance with the colorimetric method commonly used in clinical laboratories. It is simple, rapid and suitable for screening large numbers of samples, avoids the necessity of diluting the seminal plasma sample, and saves a lot of manpower and reagents.

Automation, Laboratory ; methods ; Humans ; Male ; Reproducibility of Results ; Semen ; enzymology ; gamma-Glutamyltransferase ; analysis

OBJECTIVETo investigate the epidemiological status of cholestasis in first-hospitalized patients with chronic liver disease in Shanghai, and to provide a scientific basis for developing prevention and treatment measures.

METHODSFrom April 2005 to September 2014, 5,146 first-hospitalized patients in Shanghai with a diagnosis of chronic liver disease were enrolled in this study. Clinical data of the 4,660 patients who fit the study criteria for participation were collected for retrospective analysis.Diagnosis of cholestasis was made according to serum alkaline phosphatase (ALP) levels higher than 1.5 times the upper limit normal (ULN) and gamma-glutamyltransferase (GGT) levels higher than 3 times the ULN. The incidence rate of cholestasis was assessed for relation to age, sex, etiology, and type of liver disease, and statistically compared to the general clinical data and specific biochemical indicators with potential sex-related differences. T-test and chi-square test were performed for the statistical analyses.

RESULTSOf the 4,660 study participants, 10.26% had cholestasis; the prevalence of cholestasis increased with increasing age in male patients. The distribution of the cholestasis incidence according to the type of chronic liver disease was: 75.00%, primary sclerosing cholangitis; 42.86%, primary biliary cirrhosis; 35.97%, hepatic tumor; 30.77%, autoimmune hepatitis; 28.31%, drug-induced liver disease; 16.46%, alcoholic hepatitis; 13.98%, cryptogenic cirrhosis; 12.99%, schistosomal cirrhosis; 7.53%, alcoholic cirrhosis; 7.32%, mixed cirrhosis; 5.94%, viral liver cirrhosis; 2.70%, nonalcoholic fatty liver disease. There was no significant difference in the prevalence of cholestasis between the two sexes. In the patients with cholestasis, the levels of GGT and total bilirubin were significantly different between the two sexes.

CONCLUSIONThe incidence rate of cholestasis in first-hospitalized patients with chronic liver disease was 10.26%, and the rate increased with increased age. Patients with primary sclerosing cholangitis or primary biliary cirrhosis had higher incidence rates of cholestasis. Incidence rates of cholestasis of the various chronic liver diseases were not related to sex.

Bilirubin ; China ; Cholestasis ; Chronic Disease ; Humans ; Incidence ; Liver Diseases ; Male ; Prevalence ; Retrospective Studies ; gamma-Glutamyltransferase